http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2010031002-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_639cdb1f1acfa83266e034f782aeb15b |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7008 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H5-06 |
| filingDate | 2009-07-01^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_93d48ab00697fabdeb5fbea833b0b353 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_09342290201c74a3cd0c7cbeb9dc64fa http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_92f8ef162086b5b2fdf6f6baaab42cd6 |
| publicationDate | 2010-02-12^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2010031002-A |
| titleOfInvention | Preventive and therapeutic agent for pancreatitis |
| abstract | An object of the present invention is to provide a trypsinogen activation inhibitor or a pancreatitis inhibitor that exhibits almost no side effects even when administered to a living body and exhibits a sufficient trypsinogen activation inhibitory action (or trypsin inhibitory action). The purpose is to provide preventive / therapeutic agents. A galactosamine or a derivative thereof is used. Since galactosamine or a derivative thereof has an effect of inhibiting the decomposition of trypsinogen into trypsin (trypsinogen activation) by trypsin, it can be used as a trypsinogen activation inhibitor or a prophylactic / therapeutic agent for pancreatitis. [Selection figure] None |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023126469-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NL-2030377-B1 |
| priorityDate | 2008-07-01^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 152 of 152.